Paul Tappenden BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)
The University of Sheffield
30 Regent Street
Tel: (+44) (0)114 222 0855
Fax: (+44) (0)114 272 4095
I am a Senior Research Fellow within the Health Economics and Decision Science Section at ScHARR. I have over 10 years experience in designing, developing and critically appraising health economic models across a number of disease areas. Since joining ScHARR in 2000, I have been involved in a number of research studies for the National Institute for Health and Clinical Excellence, including modelling the cost-effectiveness of beta-interferon and glatiramer-acetate in the management of multiple sclerosis, modelling the cost-effectiveness of influenza prophylaxis and modelling the cost-effectiveness of technologies for the prevention, detection, treatment and follow-up of colorectal cancer. I have also undertaken modelling assessments for the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. I have recently completed a fellowship funded by the NIHR evaluating the role and value of developing health economic models of whole disease and treatment pathways (Whole Disease Modelling).
My main research interests are:
- Health economic modelling
- Economic analyses of therapies for multiple sclerosis
- Economic analyses of cancer therapies
- Whole disease modelling
I currently teach on the MSc in Health Economics and Decision Science. I am also involved in the development of three modules for MSc in International Health Technology Assessment, Pricing and Reimbursement.
I am currently Deputy Technical Director for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit.
Amongst others, I am currently working on the following projects:
- The clinical effectiveness and cost-effectiveness of colistimethate sodium and tobramycin dry powders for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis (NICE)
- The clinical effectiveness and cost-effectiveness eculizumab for the treatment of Atypical Hemolytic Uremic Syndrome (AGNSS)
- The clinical effectiveness and cost-effectiveness home-based nurse-led health promotion for older people (NETSCC)
- The clinical effectiveness and cost-effectiveness of early awareness programmes in cancer (DH)
- MAPNICE - pathways model development in prostate cancer and atrial fibrillation (MRC)
- Joint co-ordination of the update to the NICE Methods Guide (NICE)
- Avoiding and identifying errors in health technology assessment models. Health Technology Assessment 2010;14(25) (with JB Chilcott, A Rawdin, M Johnson, E Kaltenthaler, D Papaioannou and A Shippam)
- Systematic review of economic evidence for the detection, diagnosis, treatment and follow-up of colorectal cancer in the UK. International Journal of Technology Assessment in Health Care 2009;25:470-8 (with JB Chilcott, A Brennan, and H Pilgrim)
- Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007;56:677-84 (with JB Chilcott, S Eggington, J Patnick, H Sakai and J Karnon)
- Methodological issues in the economic analysis of cancer treatments. European Journal of Cancer 2006;42:2867-75 (with JB Chilcott, S Ward, S Eggington, D Hind and S Hummel)
- Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment 2006 (with R Jones, S Paisley and C Carroll)
- Methods for expected value of information analysis in complex health economic models. Developments on the health economics of beta interferon and glatiramer acetate in the management of multiple sclerosis. Health Technology Assessment 2004;8(27) (with JB Chilcott, S Eggington, J Oakley and C McCabe)
Paul Tappenden is based in Health Economics and Decision Science (HEDS).